Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes

被引:2
|
作者
Sereda, Elena E. [1 ,2 ]
Kolegova, Elena. S. [3 ]
Kakurina, Gelena V. [1 ,2 ]
Korshunov, Dmitriy A. [1 ]
Sidenko, Evgenia A. [1 ]
Doroshenko, Artem V. [4 ]
Slonimskaya, Elena M. [4 ]
Kondakova, Irina V. [1 ]
机构
[1] Russian Acad Sci, Canc Res Inst, Tomsk Natl Res Med Ctr, Lab Tumor Biochem, Tomsk 634009, Russia
[2] Siberian State Med Univ, Fac Med & Biol, Dept Biochem & Mol Biol, Tomsk 634050, Russia
[3] Russian Acad Sci, Canc Res Inst, Tomsk Natl Res Med Ctr, Lab Canc Progress Biol, Tomsk, Russia
[4] Russian Acad Sci, Canc Res Inst, Dept Gen Oncol, Tomsk Natl Res Med Ctr, Tomsk, Russia
来源
关键词
Luminal breast cancer; hematogenous metastases; proteasomes activity; long-term outcome; prognosis; ESTROGEN-RECEPTOR-ALPHA; KAPPA-B; TARGET; PHOSPHORYLATION; UBIQUITYLATION; DEGRADATION; PROTEIN;
D O I
10.21037/tbcr-22-22
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The purpose of the study was to analyze the relationship between the caspase-like (CL) and chymotrypsin-like (ChTL) activities of proteasomes and the 5-year overall and metastasis-free survival rates in patients with luminal breast cancer. Methods: The study included 117 patients with primary operable invasive breast cancer (T1-2N0-1M0). Tissue samples from breast cancer patients were obtained as a result of the radical mastectomy or breast conserving surgery, which was a first line of therapy. The ChTL and CL proteasomes activities in the tumor tissue and in the surrounding adjacent breast tissues were assessed using the fluorometric method. The coefficients of ChTL (cChTL) and CL (cCL) proteasomes activities were also determined. The coefficients were calculated as the ratio of the corresponding proteasomes activity in the tumor tissue to the surrounding adjacent breast tissues. Within 5 years of follow-up, hematogenous metastases occurred in 14% of patients with luminal A breast cancer, in 31% of patients with luminal B human epidermal growth factor receptor-2 (HER-2) negative and in 23% of patients with luminal B HER-2 positive breast cancers. The study protocol was approved by the Local Ethics Committee of the Cancer Research Institute of Tomsk National Research Medical Center. Written informed consent was obtained from all patients. Results: An increase in the ChTL and CL proteasomes activities was shown in all studied molecular subtypes of breast cancer compared to adjacent tissues. It was found that the cChTL of >35.9 U/mg protein and the cCL of >2.21 in breast cancer patients were associated with the development of distant metastases. In patients with luminal A breast cancer, the 5-year metastasis-free survival rates were associated only with the value of cCL of proteasomes (log-rank test: P=0.008). In patients with luminal B HER-2 negative breast cancer, the 5-year metastasis-free survival rates were associated with the levels of ChTL and cCL proteasomes activities (log-rank test: P=0.02 and P=0.04, respectively). Conclusions: The data obtained on the correlation of 5-year metastasis-free survival rates with the level of proteasomes activities indicate the possibility of their use as additional prognostic criteria for breast cancer.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Five-year relative survival by stage of breast and colon cancers in Italy
    Mangone, Lucia
    Mancuso, Pamela
    Bisceglia, Isabella
    Braghiroli, Barbara
    Ferrari, Francesca
    Vicentini, Massimo
    Giorgi Rossi, Paolo
    TUMORI JOURNAL, 2021, 107 (04): : 318 - 324
  • [32] Five-year survival rate of postoperative ovarian cancer patients:a 15-year retrospective study
    Zhang Xi
    Zhang Qing
    Song Kun
    Cui Baoxia
    Jiang Jie
    Zhang Youzhong
    Wang Bo
    Zhang Xiangning
    Liu Peishu
    Yang Xingsheng
    Kong Beihua
    现代妇产科进展 , 2017, (12) : 962 - 964
  • [33] A five-year survival rate in patients with carcinoma of the cervix uteri
    Ljuca, Dzenita
    Fatusic, Zlatan
    Iljazovic, Ermina
    Ahmetovic, Begzudin
    HEALTHMED, 2007, 1 (01): : 2 - 8
  • [34] Five-year Survival With Tafamidis In Patients With Transthyretin Amyloid Cardiomyopathy
    Hoffman, James E.
    Gundapaneni, Balarama
    Sultan, Marla B.
    Elliott, Perry
    JOURNAL OF CARDIAC FAILURE, 2022, 28 (05) : S102 - S102
  • [35] Five-Year Relative Survival of Patients With Osteoporotic Hip Fracture
    Lee, Young-Kyun
    Lee, You-Jin
    Ha, Yong-Chan
    Koo, Kyung-Hoi
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (01): : 97 - 100
  • [36] Five-year leukemia survival by age
    Levi, F
    Te, VC
    Randimbison, L
    La Vecchia, C
    ANNALS OF ONCOLOGY, 1999, 10 (06) : 735 - 735
  • [37] Five-year prognosis of breast cancer patients in Conakry Hospital University (West Africa)
    Traore, Bangaly
    Toure, Abdoulaye
    Sy, Telly
    Dieng, Mamadou Moustapha
    Conde, Mamoudou
    Dem, Ahmadou
    Keita, Namory
    Sylla, Bakary Sidiki
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] FIVE-YEAR RESULTS OF THE BREAST CANCER SCREENING PROGRAMME IN UGRA
    Zakharova, N. A.
    Duffy, S. W.
    Mackay, J.
    Kotlyarov, E. V.
    Filimonov, A. V.
    Barinov, K.
    Gromut, I.
    Belan, E. V.
    ANNALS OF ONCOLOGY, 2012, 23 : 470 - 470
  • [39] Relation of Body Mass Index to Five-Year Survival in Patients With ST-Elevation Myocardial Infarction
    Kozieradzka, Anna
    Kaminski, K. A.
    Dohrzycki, S.
    Musial, W. J.
    AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103 (03): : 435 - 435
  • [40] Five-year outcome of interstitial brachytherapy in the management of breast cancer patients treated with breast conserving surgery
    Aslay, I
    Özbilen, S
    Karnap, M
    Özbay, I
    Tenekeci, N
    Dincer, M
    Özturk, N
    Tuzlali, S
    Ilhan, R
    Töre, G
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S210 - S210